X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs BIOCON LTD - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA BIOCON LTD SUN PHARMA/
BIOCON LTD
 
P/E (TTM) x 37.3 90.9 41.0% View Chart
P/BV x 4.0 7.7 51.6% View Chart
Dividend Yield % 0.3 0.2 211.3%  

Financials

 SUN PHARMA   BIOCON LTD
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
BIOCON LTD
Mar-18
SUN PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs7011,188 59.0%   
Low Rs433305 142.0%   
Sales per share (Unadj.) Rs110.468.7 160.7%  
Earnings per share (Unadj.) Rs11.07.6 145.4%  
Cash flow per share (Unadj.) Rs17.214.0 123.3%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.40.1 263.4%  
Book value per share (Unadj.) Rs158.886.3 183.9%  
Shares outstanding (eoy) m2,399.26600.00 399.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x5.110.9 47.3%   
Avg P/E ratio x51.698.9 52.2%  
P/CF ratio (eoy) x32.953.4 61.6%  
Price / Book Value ratio x3.68.6 41.3%  
Dividend payout %18.213.2 137.6%   
Avg Mkt Cap Rs m1,360,021447,900 303.6%   
No. of employees `00017.86.1 289.3%   
Total wages/salary Rs m53,6719,311 576.4%   
Avg. sales/employee Rs Th14,890.96,705.8 222.1%   
Avg. wages/employee Rs Th3,017.11,514.2 199.2%   
Avg. net profit/employee Rs Th1,480.6736.9 200.9%   
INCOME DATA
Net Sales Rs m264,89541,234 642.4%  
Other income Rs m8,3882,062 406.8%   
Total revenues Rs m273,28243,296 631.2%   
Gross profit Rs m56,0818,291 676.4%  
Depreciation Rs m14,9983,851 389.5%   
Interest Rs m5,176615 841.6%   
Profit before tax Rs m44,2955,887 752.4%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4521,569 538.7%   
Profit after tax Rs m26,3384,531 581.3%  
Gross profit margin %21.220.1 105.3%  
Effective tax rate %19.126.7 71.6%   
Net profit margin %9.911.0 90.5%  
BALANCE SHEET DATA
Current assets Rs m316,35941,486 762.6%   
Current liabilities Rs m198,64321,413 927.7%   
Net working cap to sales %44.448.7 91.3%  
Current ratio x1.61.9 82.2%  
Inventory Days Days9564 148.2%  
Debtors Days Days10894 114.3%  
Net fixed assets Rs m213,17850,661 420.8%   
Share capital Rs m2,3993,000 80.0%   
"Free" reserves Rs m378,60648,808 775.7%   
Net worth Rs m381,00651,808 735.4%   
Long term debt Rs m17,72117,898 99.0%   
Total assets Rs m643,02899,897 643.7%  
Interest coverage x9.610.6 90.4%   
Debt to equity ratio x00.3 13.5%  
Sales to assets ratio x0.40.4 99.8%   
Return on assets %4.95.2 95.1%  
Return on equity %6.98.7 79.0%  
Return on capital %10.09.6 104.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81612,058 338.5%   
Fx outflow Rs m30,1437,348 410.2%   
Net fx Rs m10,6734,710 226.6%   
CASH FLOW
From Operations Rs m39,0726,621 590.1%  
From Investments Rs m-33,708-6,840 492.8%  
From Financial Activity Rs m-15,393-2,397 642.2%  
Net Cashflow Rs m-7,359-2,612 281.7%  

Share Holding

Indian Promoters % 63.7 40.4 157.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 5.1 8.4 61.1%  
FIIs % 23.0 10.7 215.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 19.9 41.7%  
Shareholders   133,026 109,995 120.9%  
Pledged promoter(s) holding % 0.5 0.0 1,325.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

BIOCON LTD share price has hit an all time high at Rs 696 (up 1.4%). The BSE HEALTHCARE Index is down by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 1.4%) and SANOFI INDIA (up 2.6%). The top losers include TORRENT PHARMA (down 0.1%) and AUROBINDO PHARMA (down 0.2%).

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 24, 2018 12:57 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS